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Abstract: Transcription is a crucial step for hu-
man immunodeficiency virus type 1 (HIV-1) ex-
pression in all infected host cells, from T lympho-
cytes, thymocytes, monocytes, macrophages, and
dendritic cells in the immune system up to micro-
glial cells in the central nervous system. To maxi-
mize its replication, HIV-1 adapts transcription of
its integrated proviral genome by ideally exploiting
the specific cellular environment and by forcing
cellular stimulatory events and impairing tran-
scriptional inhibition. Multiple cell type-specific in-
terplays between cellular and viral factors perform
the challenge for the virus to leave latency and
actively replicate in a great diversity of cells, de-
spite the variability of its long terminal repeat re-
gion in different HIV strains. Knowledge about the
molecular mechanisms underlying transcriptional
regulatory events helps in the search for therapeu-
tic agents that target the step of transcription in
anti-HIV strategies. J. Leukoc. Biol. 74: 736–749;
2003.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) replication is
regulated by multiple events occurring at different steps of the
viral life cycle [1]. After fusion-mediated entry within host
cells, uncoating, reverse transcription of the RNA genome and
nuclear entry of the preintegration complex, the proviral DNA
is integrated into the host cell genome. Transcription of the
HIV-1 provirus is then regulated by an interplay between a
combination of distinct viral and cellular transcription factors
with binding sites present in the HIV-1 long terminal repeat
(LTR; for review, see refs. [2–4]). The LTR is divided in
functional regions designated by transactivation response ele-
ment (TAR), core, enhancer, and modulatory elements. The
TAR region binds the viral transactivator Tat and the core
region contains the initiator (Inr), the TATA box, and three
Sp1-binding sites. While the enhancer element binds nuclear
factor (NF)-B and NF of activated T cells (NF-AT) transcrip-
tion factors, the modulatory region harbors numerous target
sequences for a variety of cellular transcription factors such as
NF–interleukin (IL)-6, cyclic AMP (cAMP) response element-
binding protein (CREB), Ets, and nuclear hormone receptors.
These host-cell factors regulate LTR-driven transcription not
only by direct binding to their target DNA sequence but also by
indirect binding via DNA-bound proteins. Extensive studies
have described how cis- and trans-acting elements regulate
LTR-driven transcription, but few have focused on the ability
of the viral genome to adjust its transcriptional mechanism to
each specific cell type.
This review highlights the extraordinary capacity of HIV to
adapt its transcriptional strategy to different cellular environ-
ments. We describe the mechanisms underlying the cell type-
specific transcription directed by the HIV-1 LTR in T4 lym-
phocytes, thymocytes, monocytes, macrophages, and microglial
cells. In addition, we present LTR variations in different HIV-1
isolates. New advances suggest that the transcription step of
the viral life cycle could be used as a target for an anti-HIV
strategy.
CELLULAR SPECIFICITY OF HIV-1 GENE
TRANSCRIPTION
When the HIV-1 provirus is integrated in the host genome,
early-phase transcription is regulated by cellular transcription
factors and results in the production of early viral gene prod-
ucts. The late phase of transcription is under the control of Tat,
which potently enhances gene expression by a direct binding to
TAR–RNA and association with cyclin T1 (CycT1), which
recruits the cyclin-dependent kinase 9 (cdk9). Formation of
this positive transcription-elongation factor b (P-TEFb) com-
plex leads to the phosphorylation of the C-terminal domain of
RNA polymerase II (RNAPII) and efficient elongation. These
two steps of proviral transcription occur in various cell types,
which indicate that distinct combinations of factors mediate
transcription in a cell type-specific manner.
REGULATION OF HIV-1 TRANSCRIPTION
BY CELLULAR TRANSCRIPTION FACTORS
The following studies illustrate the high complexity and the
cell-type specificity of the early phase of HIV-1 gene transcrip-
tion.
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Sp1-mediated regulation of LTR-driven
transcription
Transcription factors of the Sp1 multigene family [5, 6] mod-
ulate HIV-1 gene transcription by direct binding to the three
GC boxes adjacent to the TATAA sequence. The Sp1 factor is
one of the essential cellular proteins implicated in HIV-1 gene
transcription [7–9]. Although Sp1 and Sp4 function as tran-
scriptional activators, the Sp3 protein represses the HIV pro-
moter activity in HeLa cells [10]. Sp1 and Sp3 proteins are
expressed in microglial cells and exert an antagonist action on
LTR-driven transcription. In addition, Sp3 is able to repress
not only the Sp1 action but also the positive action of the
transcription factor chicken ovalbumin upstream promoter
transcription factor (COUP-TF), exerted via binding to Sp1 as
discussed below [11].
In U1 monocytic cells, in vivo footprinting analysis confirms
the importance of the Sp sites for LTR-driven transcription in
living cells [12]. It is interesting that monocytic cells that differ
in their degree of differentiation present a large difference in
the binding of Sp1 and Sp3 to the Sp site III [13]. Moreover,
recruitment of members of the Sp family is of greater impor-
tance in T cells as compared with monocytic cells, as substi-
tution of low-affinity Sp sites in place of the natural site III
decreases viral replication in Jurkat T cells and has small
effects in U937 monocytes [14]. Thus, modulation of HIV-1
gene transcription by proteins of the Sp family depends on the
nature of the Sp protein bound to the LTR, on the cell type as
well as on the differentiation state of the infected cell.
A number of studies report that the Sp1 protein can serve as
an anchor for indirect binding of transcription factors. In
microglial and Jurkat T cells, the Sp1 protein interacts directly
with COUP-TF to synergistically stimulate transcription [11,
15]. Sp1 is also able to functionally interact with NF–IL-6,
which leads to a mutual inhibition in microglial cells and to a
synergistic transcriptional stimulation in glial cells [16]. In
addition, a cooperative interaction between Sp1 and NF-B,
bound to the adjacent sites, is required for optimal HIV-
enhancer activation [17]. In all cell types, an interaction be-
tween Sp1 and Tat is required for optimal Tat transactivation
[18, 19]. Finally, Sp1 is able to recruit the CycT1 subunit of
P-TEFb to the LTR, which helps bypass a requirement for
TAR/Tat and promotes processive transcription without Tat
[20].
Two adjacent Sp1-binding sites located in the 724/743
LTR region downstream of the transcription start site also play
a positive regulatory role on HIV transcription. Proviruses
containing mutations in these sites are totally defective for viral
replication in T lymphoid cells [21]. Taken together, these
observations highlight the capacity of Sp1 to stimulate tran-
scription by acting at distinct sites within the LTR, to recruit
cellular factors to the LTR, and to promote Tat-mediated
transactivation. Thus, Sp1 appears as a crucial cellular tran-
scription factor for efficient HIV-1 gene transcription.
NF-B-mediated stimulation of LTR-driven
transcription
NFs of the B family are involved in the control of a variety of
cellular processes, such as immune and inflammatory re-
sponses, development, cellular growth, and apoptosis. A large
number of stimuli activate the NF-B pathway (for review, see
ref. [22]). Upon induction, NF-B, composed of p50 and p65
(RelA) subunits, is liberated from its cytoplasmic inhibitor IB
and translocated in the nucleus where it binds to the two
NF-B target sequences within the LTR.
The importance of this factor in unstimulated Jurkat T cells
and in microglial cells is revealed by the deletion of the two
LTR NF-B sites, which results in a drastic decrease of the
level of transcription [11, 23]. Similarly, in cells of the mono-
cytic lineage, occupancy of the enhancer by NF-B p50/p65
heterodimers is required for transcription [24]. However, upon
phorbol ester and calcium ionophore activation, NF-B or Sp1
mutant viruses are still able to replicate in CD4 T cells [25].
In fact, mutations in the B-binding sites impair virus produc-
tion in cells with a high basal level of NF-B such as Jurkat T
cells [26]. In CD4 T lymphocytes, the NF-B pathway is
induced by myeloid-related proteins, highly expressed by my-
eloid cells in the serum of HIV-1-infected patients [27].
In thymocytes, activation of the NF-B factors is mediated
by tumor necrosis factor  (TNF-) and IL-1 and IL-7, present
in the thymic microenvironment, and is required for a high
level of transcription. When the B sites are deleted, the HIV
provirus fails to replicate, which shows the requirement of
NF-B for viral expression in thymocytes [28].
A new link among cytokine signaling, the dopamine system,
and transactivation of the LTR via the involvement of NF-B
was reported in Jurkat T cells and peripheral blood mononu-
clear cells (PBMCs) [23]. It is interesting that HIV-1 surface
proteins can also contribute to support viral replication by
stimulating the NF-B pathway. HIV-1 virions incorporate
several surface proteins of host origin. Incubation of human T
lymphoid cells with viruses bearing host-derived B7-2 proteins
potently activates LTR-driven transcription via the NF-B and
the NF-AT pathways [29].
Moreover, NF-B-mediated induction of LTR transcription
includes a recruitment of histone acetyl transferase activity
[30, 31]. As described for Tat and Sp1, NF-B also has the
ability to recruit P-TEFb and to stimulate the elongation step
of transcription by RNAPII [32]. This P-TEFb recruitment by
Sp1 and NF-B in preinitiation complexes before the synthesis
of TAR–RNA and P-TEFb targeting to the LTR can substitute
for the lack of transcriptional elongation in the absence of Tat
[33].
NF-AT-mediated regulation of LTR-driven
transcription
Similar to NF-B, NF-AT relocalizes to the nucleus following
cellular activation. NF-AT proteins are dephosphorylated by
the calcium-activated phosphatase calcineurin, undergo nu-
clear translocation, and then assemble with activated protein-1
(AP-1) [34]. NF-AT proteins bind the NF-B sites of the LTR
region. The two proteins NF-AT1 and NF-AT2/NF-ATc appear
to have contrasting effects in different cell types. NF-AT1 acts
as an activator of LTR-driven transcription in primary CD4 T
cells, especially in the CD4 memory T cell subset [35, 36]. In
Jurkat T cells, NF-AT1 appears to regulate NF-B-mediated
transactivation negatively, by competing with NF-B for its
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LTR-binding sites, and to repress Tat-mediated transactivation
by interacting with Tat [37].
NF-AT2 /NF-ATc is sufficient to induce a highly permissive
state for HIV-1 replication in primary CD4 T cells [38].
While in resting, naı¨ve lymphocytes, HIV-1 gene transcription
appears repressed, in activated T lymphocytes, the NF-B and
NF-AT sites of the LTR mediate transcriptional activation [39].
NF-AT2 binds to the NF-B sites of the LTR and synergizes
with NF-B and Tat in the transcriptional activation and
HIV-1 replication [38]. NF-AT proteins also interact with Ets
transcription factors, which results in a cooperative activation
of LTR-driven transcription [40]. Moreover, activation of NF-
AT-dependent HIV gene expression appears to be stimulated
by the viral Nef protein [41, 42].
Lymphoid enhancer-binding factor (LEF-1)/T cell-
specific factor-1 (TCF-1)-mediated regulation
of LTR-driven transcription
LEF-1/TCF-1 [43] is described as an activator of LTR-driven
transcription in T lymphocytes [44]. Mutations in the LEF-
binding site located in the enhancer region of the LTR (–122/–
142) inhibit the transcriptional activity of the HIV-1 enhancer
in Jurkat T cells [44]. In vitro, LEF-1 binds to this LTR-
binding site in a nucleosomal context [45]. Moreover, recom-
binant LEF-1 protein counteracts chromatin repression, indi-
cating that transcriptional activation by LEF-1 in vitro is a
chromatin-dependent process [44].
CCAAT/enhancer-binding protein (C/EBP)-
mediated regulation of LTR-driven transcription
Another example of cell type-specific transcriptional modula-
tion of the HIV-1 genome is documented by studies on the
C/EBP family of transcription factors. Two C/EBP-binding
sites are centered around positions –170 and –110 of the LTR.
The human NF–IL-6 protein (corresponding to the mouse
C/EBP protein) plays a central role in the control of HIV
infection in cells of the immune system. The LTR-binding sites
and the C/EBP/NF–IL-6 proteins are required for full NF–IL-6
responsiveness and viral replication in promonocytic U937
cells [46, 47] in primary macrophages but not in CD4 T
lymphocytes [48].
Infected macrophages interact with neighboring cell popu-
lations, such as endothelial cells, through inflammatory medi-
ators and direct cell contact, which create a microenvironment
favorable for HIV replication. In the presence of endothelial
cells, the enhancement of viral replication is mediated by
C/EBP, necessary for efficient LTR activity [49]. Moreover,
after infection with Mycobacterium tuberculosis, monocytes pro-
duce a stimulatory 37-kDa C/EBP transcription factor that
enhances HIV-1 replication, whereas macrophages produce an
inhibitory 16-kDa C/EBP that suppresses HIV replication
[50]. Thus, differentiation of monocytes to macrophages
switches the opportunistic infection effect on HIV replication
from stimulation to inhibition by affecting expression of the
C/EBP proteins. As described in monocytic cells, C/EBP pro-
teins regulate transcription by recruiting coactivators such as
histone acetyltransferases to the LTR [51].
Two members of the C/EBP family, NF–IL-6 and C/EBP,
are expressed in microglial and glial cells of the central ner-
vous system (CNS). Although NF–IL-6 acts as a potent activa-
tor of LTR-driven transcription, C/EBP, which lacks a tran-
scriptional activation domain, acts as a dominant-negative and
inhibits NF–IL-6-mediated transactivation. Therefore, the re-
spective level of these two proteins as well as the level of
cytokines such as IL-1, IL-6, and TNF-, known to be in-
creased during HIV infection and to increase the level of
NF–IL-6, appear critical in the regulation of LTR-driven tran-
scription [40].
It is interesting that transactivation by NF–IL-6 can bypass
a requirement for direct interaction of NF–IL-6 to its DNA-
binding sites, through cooperation with Sp1, NF-B, and
CREB proteins or via the basal transcriptional machinery [16,
52–54]. In microglial cells, endogenous NF–IL-6 appears un-
able to interact with its –170 LTR site, as the upstream
stimulatory factor (USF) protein binds to the overlapping E site
and competes with NF–IL-6 for binding. In microglial and in
Jurkat T cells, NF–IL-6 stimulates transcription via the Sp1
sites of the LTR [16, 54]. Functional interactions between Sp1
and NF–IL-6 proteins lead to a mutual repression in microglial
cells and to a synergistic stimulation in glial cells [16]. In T
cells, the C/EBP-binding sites and the cooperative action be-
tween NF–IL-6 and CREB mediate prostaglandin E2-induced
stimulation of LTR-driven transcription [55]. In cells of mono-
cyte/macrophage lineage, NF–IL-6 also associates and het-
erodimerizes with CREB [53].
CREB-mediated regulation of LTR-driven
transcription
The importance of the cAMP pathway during the course of
HIV-1 infection is well established, as cAMP levels are higher
in seropositive patients [56]. HIV-1 infection of T cell lines
[57] and primary lymphocytes [56] leads to an increase in
intracellular levels of cAMP. This increase in cAMP levels
activates the CREB/activating transcription factor (ATF) family
through protein kinase A (PKA)-mediated phosphorylation.
This phospho-CREB then recruits the adaptor CREB-binding
protein (CBP) and basal transcription factors, which lead to
increased promoter activation (for review, see ref. [58]). HIV
infection rapidly increases CREB/ATF-binding activity and
levels of CREB/ATF proteins in a T cell line infected by HIV-1
[59]. In latently infected promonocytic U1 cells, the cAMP/
PKA and the PKC signaling pathways synergize to increase
LTR transactivation and viral replication [60]. In the same
cells, cAMP also potentiates TNF- induction of HIV tran-
scription [61].
A recognition sequence for members of the CREB/ATF
family was identified between the LEF-1 and the NF-B sites
[62]. Two other CREB/ATF-binding sites that also bind AP-1
are located downstream of the transcription initiation site, at
positions 92/102 and 160/167 of the U5 LTR region
[59]. In cells of monocyte/macrophage lineage, CREB ho-
modimers bind to their DNA site and recruit C/EBP dimers;
CREB and C/EBP/NF–IL-6 also heterodimerize and bind to
their respective LTR sites. In these cells, sequence variations
at the CREB site affect LTR activity [53]. In contrast, in Jurkat
T cells, CREB does not act via its DNA site but mediates
cAMP and dopamine-induced transcriptional stimulation
through indirect interactions with the –40/80 region of the
738 Journal of Leukocyte Biology Volume 74, November 2003 http://www.jleukbio.org
LTR. Moreover, functional interactions between CREB and the
nuclear receptor COUP-TF lead to synergistic activation of
HIV-1 gene transcription in the presence of forskolin, cAMP,
and dopamine [15]. In addition to its effect on the PKA
pathway and LTR-driven transcription, cAMP also induces
up-regulation of cell-surface CXCR4 coreceptors and renders
T lymphocytes more vulnerable to CXCR4-tropic HIV-1 infec-
tion [63].
USF- and Ets-mediated stimulation of LTR-
driven transcription
USF stimulates transcription through the TAR–DNA region,
the Inr element, and the positions –173 to –157 upstream of
the transcription start site of the LTR in vitro [64, 65]. USF
binds to the E-box overlapping the –170-centered C/EBP
region and competes with NF–IL-6 for binding [16, 65, 66].
Although USF activates HIV-1 transcription in a T cell line, it
acts as an inhibitor in an epithelial cell line [67].
The two Ets (–95/–104 and –140/–160)-binding sites of the
LTR mediate Ets-mediated activation of HIV-1 gene transcrip-
tion [68]. Interaction between Ets-1 and USF-1 is required for
full transcriptional activity of the HIV-1 LTR in T cells [69].
Confirming the previous observations, the dominant-negative
mutant of Ets-1 markedly suppresses HIV-1 infection in T
cells [70].
Nuclear hormone receptors mediated regulation
of LTR-driven transcription
Various members of the steroid-thyroid-retinoid nuclear recep-
tor superfamily modulate HIV-1 transcription by distinct mo-
lecular mechanisms in different cells. The nuclear receptor
responsive element (NRRE) is located within the distal –356/
–320 region of the LTR [71–74]. The retinoic acid receptors
(RAR and RXR) stimulate transcription in the presence of
their ligand via the NRRE site in choriocarcinoma cells [72]
and in CV1 cells [73]. In oligodendroglioma cells, RAR and
RXR activate transcription in the absence of ligand. Addition
of ligands reverses this effect. This retinoid response is medi-
ated by distinct molecular interaction with the LAI and the
JR-CSF HIV-1 strains [75]. In microglial cells, no significant
effect of the retinoid pathway could be detected [75].
Distinct LTR sites are able to mediate the response to RA,
independently of the NRRE sequence. In U937 monocytes, RA
activation is mediated by the proximal –83/80 LTR region in
the presence of phorbol esters [phorbol 12-myristate 13-acetate
(PMA); ref. 76]. In contrast, RA inhibits HIV gene transcrip-
tion via the NF-B responsive element in untreated U937
monocytes and HeLa cells [77]. RA, like arsenic trioxide,
induces the remission of acute promyelocytic leukemia, result-
ing from a fusion of the RAR and the promyelocytic leukemia
(PML) genes (for review, see refs. [78, 79]). Arsenic activates
HIV-1 replication by enhancing reverse transcription and dis-
rupting PML cellular localization [80, 81]. The PML protein
regulates Tat transactivation by modulating CycT1 availability
to the transcriptional machinery [82]. Thus, as described for
arsenic, RA may also impact HIV-1 gene expression indepen-
dently of LTR-binding sites by targeting PML function.
The LTR is activated by thyroid hormone T3 receptors (T3R)
in the absence of ligand in CV1 green monkey kidney cells.
This activity is mediated by a direct binding of T3R to the
Sp1-binding region, which also functions as a thyroid hormone
receptor response element [83, 84]. Recent results suggest that
chromatin remodeling, including histone acetylation and chro-
matin disruption, is important for T3 regulation of the HIV–
LTR in vivo [85]. In microglial cells, no T3R was detected [11],
and overexpression of T3R did not alter the LTR activity
(unpublished results).
Administration and/or excess secretion of glucocorticoids
have been associated with increased HIV-1 replication and
AIDS progression. Recombinant glucocorticoid receptors in-
teract with the glucocorticoid receptor responsive element
(GRE) located within the –259/–264 region of the LTR [86]. In
CEM T4 cells, transcription is slightly up-regulated by dexa-
methazone treatment and in contrast, is repressed in promono-
cytes [87, 88].
Protease inhibitors used in highly active antiretroviral ther-
apy (HAART) create several metabolic disorders. Agonists of
peroxisome proliferator-activated receptor (PPAR) are being
studied in HAART-related metabolic disorders. The inhibitory
effect of PPAR and PPAR agonists on HIV-1 replication has
been shown in monoblastoid U1 cells, PBMCs, and macro-
phages [89, 90]. These results suggest that modulation of
PPAR activity by their agonists may improve the metabolic
alterations following HAART in conjunction with the desirable
decreases in viral replication.
COUP-TF [91] is an orphan member of the nuclear receptor
superfamily. It is the major species bound to the NRRE region
of the LTR in microglial and glial cells of the brain [11, 92], as
well as in monocytes THP1 and HL-60 (unpublished results).
Distinct cell-type and HIV strain-specific mechanisms govern
COUP-TF-induced stimulation. COUP-TF functions as an ac-
tivator of HIV-1 gene transcription in T cells, microglial cells,
and oligodendroglioma but not in astrocytoma [11, 92]. In
microglial cells, COUP-TF stimulates LTR-driven transcrip-
tion independently of its binding to the NRRE region by a
direct interaction with the Sp1 protein bound to its LTR site.
Similarly, overexpressed COUP-TF in Jurkat T cells also acts
via Sp1 [11, 15]. In contrast, in oligodendroglioma cells, the
NRRE site is required for COUP-TF action, as mutation of the
NRRE sequence, as found in the JR-FL and JR-CSF strains,
prevents COUP-TF-mediated transcriptional stimulation [92].
AP-1-mediated regulation of LTR-driven
transcription
The AP-1 family of oncoproteins Jun and Fos are tetradecanoyl
phorbol acetate (TPA)-inducible transcription factors known to
interact with the TGACTCA consensus sequence. Three AP-
1-binding sites identified in the 92/167 LTR region down-
stream of the transcription start site appear important for viral
infectivity [21, 93]. However, within the modulatory region of
the LTR, the two –352/–324 and –306/–285 consensus sites
are unable to directly bind AP-1 proteins present in various
cell types. AP-1 interacts indirectly with the NRRE region and
modulates HIV transcription via members of the nuclear re-
ceptor family [75]. AP-1 components present in glial and HeLa
cells but not AP-1 present in Jurkat T cells interact with a
TPA-responsive element (TRE)-like sequence located at posi-
tions –242/–222 in the LTR of JR-FL and JR-CSF strains and
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absent in the LAI strain [74]. This interaction mediates c-Jun-
induced transcriptional activation in glial cells. However, no
AP-1-induced activation is detected in Jurkat T cells (ref. [94]
and unpublished results). These data show the flexibility of the
virus to use, or not, the AP-1 transcription factor, depending of
the cell type. Recently, the viral Nef protein has been shown to
stimulate the AP-1 pathway [95].
TAR–DNA-mediated inhibition of LTR-driven
transcription
Certain cellular proteins such as lipopolysaccharide (LPS)-
binding protein (LBP)-1 and TAR–DNA-binding protein-43
(TDP-43) are able to block HIV transcription. LBP-1 inhibits
the binding of the general transcription factor transcription
initiation factor IID (TFIID) to the TATA element [96]. TDP-43
binds to the –18/80 TAR–DNA sequence of the LTR and
inhibits HIV transcription in the absence or the presence of Tat
by blocking the assembly of transcription complexes that are
capable of responding to Tat [97, 98].
Yin Yang 1 (YY1)- and lisofylline (LSF)-mediated
inhibition of LTR-driven transcription
The cellular transcription factor YY1 has the ability to activate
or repress gene expression. In the context of the HIV-1 LTR,
YY1 functions as a repressor of gene transcription and viral
replication. The YY1 protein cooperates with LSF (CP-2, LBP-
1c, or UBP) in recognition of the –10/27 LTR region in CEM
lymphocytes, U937 monocytes, COS-1, and HeLa–CD4 cells
[99, 100]. The two factors inhibit HIV-1 gene expression by
recruitment of histone deacetylase 1 to the LTR nucleosome 1,
which counteracts Tat activation [101, 102].
P53-mediated inhibition of LTR-driven
transcription
The tumor suppressor p53 regulates cell-cycle progression and
transcription of various viral and cellular promoters [103]. p53
has been suggested to be a host suppressor of HIV-1 activation,
as overexpression of wild-type p53 inhibits the basal activity of
the HIV–LTR in HeLa cells [103]. The LTR core region is
involved in the p53-mediated repression [104, 105]. p53 also
associates with Tat and acts as a potent suppressor of Tat
transactivation [106]. In contrast, mutant forms of p53 stimu-
late expression from the LTR [104, 105, 107]. Inhibition of
HIV-1 replication by overexpressed wild-type p53 is detected
in Jurkat, SupT1 T cells, and microglial cells (unpublished
results).
REGULATION OF HIV-1 TRANSCRIPTION
BY VIRAL PROTEINS
Effect of Tat
The transactivating function of the viral Tat protein requires
the presence of the Sp1 and NF-B sites [9] and a direct
interaction with the Sp1 protein [18, 19] (for review, see refs.
[108, 109]). In addition, Tat associates with various coactiva-
tors such as CBP/p300 [110–112], pCAF [111], and hGCN5
[113], which help Tat activate transcription of integrated viral
DNA and derepress the HIV-1 chromatin structure in response
to histone acetylation [114]. Moreover, Tat associates with
distinct transcription factors, depending on the cell type and
the LTR sequence. In microglial cells, Tat physically interacts
and cooperates with COUP-TF to promote NF-B and Sp1-
independent transactivation. This interaction leads to an alter-
native pathway for Tat transactivation, in the case of LTR
mutations that abolish Sp1 or NF-B binding [115]. Tat-
dependent transcription is regulated in a cell-cycle-dependent
manner. While in the G1 phase, Tat transactivation is TAR-
dependent and requires a functional Sp1-binding site; in G2, a
second TAR-independent phase of Tat transactivation is ob-
served [116].
Tat has the ability to modulate the expression of various
cellular factors involved in the regulation of the HIV-1 gene
transcription. Tat sets up positive up-regulatory loops, which
greatly superactivate HIV transcription by activating NF-B in
different cell types [117–119] and up-regulating several cyto-
kine genes such as TNF-, TNF-, IL-2, and IL-6 (for review,
see refs. [120, 121]). In macrophages and astrocytes, an expo-
sure to Tat results in prolonged cytokine production main-
tained by a positive-feedback loop of Tat-induced NF-B
activation [122]. Induction of IL-8 in T cells by Tat is also
mediated through NF-B [123]. Tat activates NF-B through
degradation of the inhibitor IB, which requires the function
of the cellular interferon (IFN)-inducible protein kinase PKR
[124].
In addition to its action on NF-B, Tat up-regulates the IL-6
gene and interacts with the induced NF–IL-6 protein that
activates LTR-driven transcription [125]. A reciprocal, modu-
latory interplay takes place between Tat and NF-AT1 in Jurkat
T cells: Tat enhances NF-AT1-driven transcription, and NF-
AT1 represses Tat-mediated transactivation of the LTR [37].
Tat induces nitric oxide synthase via the NF-B and C/EBP
pathways in glial cells [126]. Moreover, Tat impairs the Tat
suppressor functions of p53 by a dual action: It inhibits the
transcription of the p53 gene [106] and the p300-mediated
acetylation of the p53 protein [127].
Tat affects not only the infected host cells but also when
secreted, noninfected, bystander cells. Tat-stimulated micro-
glial cells release proinflammatory molecules and accumulate
free radicals [128]. Tat activates bystander endothelial cell
E-selectin expression via a NF-B-dependent mechanism
[129].
Although most of Tat-associated proteins function as posi-
tive factors (for review, see ref. [130]), some of them are able to
act as repressors [98, 102, 131]. In microglial cells, Tat func-
tion and HIV-1 replication can be repressed by overexpression
of the nuclear corepressor COUP-TF-interacting protein 2
(CTIP2), which associates with heterochromatin protein
(HP)1 and relocalizes Tat within inactive regions of the
chromatin [132].
Effect of Vpr
The Vpr gene product participates in nuclear transport of the
preintegration complex, which empowers HIV to infect and
replicate in nondividing cells, particularly in macrophages
[133, 134]. Vpr is important for efficient viral replication in
tissue macrophages but not in nondividing CD4 T cells [135].
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Vpr functions as a positive regulator of HIV-1 gene tran-
scription, as virion-associated Vpr arrests the cell cycle of
infected cells in the G2 phase, which optimizes LTR-directed
gene transcription and cooperates with Tat to enhance HIV
transcription [136, 137]. The ability of Vpr to activate tran-
scription is mediated by the p300 coactivator [138] and by
linking the GR to the p300 coactivator in monocytes [139,
140]. The association of Vpr with Tat and CycT1 also stimu-
lates LTR-driven transcription [141]. Vpr, expressed de novo
or released from virion following entry, also enhances gene
expression from integration-incompetent, unintegrated viral
DNA generated during infection [142]. Moreover, Vpr induces
changes in transcriptional patterns through modulation of the
state of the target cell (for review, see ref. [143]).
Effect of Nef
The viral protein Nef displays multiple functions and acts as a
master switch, forcing an environment conducive to dynamic
viral production. It has no direct effect on HIV-1 gene tran-
scription but participates in the enhancement of viral expres-
sion by up-regulating the expression of factors that positively
regulate LTR-driven transcription such as NF-AT [41], NF-B,
AP-1 [95], signal transducer and activator of transcription-1
(STAT1) [144], and cdk9 [145].
REGULATION OF HIV-1 TRANSCRIPTION
IN DIFFERENT CELL TYPES
This paragraph provides a summary of the major transcription
factors that are implicated in HIV gene expression in distinct
cell types productively infected in the immune system and CNS
(Fig. 1). Although a number of negative-acting factors (pre-
sented under the schematic LTR) can inhibit transcription, it
appears that the activators (shown above the LTR region)
usually win the competition. In addition to the balance between
cellular activators and inhibitors, microenvironmental factors
including cytokines and the differentiation state of the host
cells are also critical for modulating the level of early-phase
transcription. It is interesting that the majority of the binding
sites on the LTR is not required for HIV transcription. Within
Fig. 1. Interactions of endogenous cellular transcrip-
tion factors with the HIV-1 LTR and their effect on
transcription in T4 lymphocytes, monocytes/macro-
phages, and microglial cells. The major binding sites
within the –356 to 27 region of the LTR are located.
Cellular factors that affect transcription by direct bind-
ing to the LTR are in black letters. Cellular factors that
act indirectly on the LTR via protein–protein interaction
are in white letters. Activators are represented above the
sites, and inhibitors are placed under the schematic
LTR. Transcription factors that interact with sites lo-
cated downstream of the initiation site are presented in
ref. [21]. In monocytes and macrophages, distal LTR-
binding sites downstream of the NF-B sites are essen-
tial for efficient transcriptional activation. In contrast, in
microglial cells, the core region and the NF-B sites are
sufficient for efficient transcription.
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each cell type, transcription can be mediated by a small
combination of cell type-specific transcription factors.
T lymphocytes and thymocytes
In T lymphocytes, the core region of the LTR that binds Sp1
and general transcription factors is not sufficient by itself to
mediate transcription. Only upon activation of T cells that
leads to the nuclear translocation of NF-B and NF-AT pro-
teins does the LTR become able to activate expression of the
viral genome. Thus, the enhancer region of the LTR that binds
cellular proteins such as NF-B and NF-AT is absolutely
required for transcriptional activation. In addition, NF–IL-6,
CREB, USF, and Ets contribute to full activation.
The thymus is the primary organ in which T cells mature.
Depletion of circulating CD4 T cells partly results from
infection of the thymus. Thymic infection leads to thymocyte
depletion by apoptosis and also to destruction of T cell pro-
genitors by direct infection [146, 147]. In thymocytes, LTR-
driven transcription and viral replication require activation of
NF-B by various cytokines provided by the thymic microen-
vironment [28].
Monocytes/macrophages and dendritic cells (DC)
In the monocyte/macrophage lineage, the NF–IL-6 and/or USF
proteins bound to the LTR modulatory region appear essential
for HIV-1 gene transcription, in addition to NF-B and Sp1.
Moreover, in these cells, the state of differentiation regulates
viral expression by affecting the level of CycT1 and thus, the
transactivating function of Tat [148]. In addition, in monocyte/
macrophages cells, Vpr is essential for efficient viral replica-
tion.
DC residing within epithelial surfaces are likely the first
cells infected after mucosal exposure, and DC derived from
blood interact with HIV virions crossing the mucosae. DC
efficiently process and present viral antigenic determinants to
activate specific antiviral T and B cell immunity (for review,
see ref. [149]). The developmental stage of DC influences the
extent to which HIV-1 can replicate. Although mature DC and
blood monocytes [150] do not replicate HIV-1, immature DC
can be productively infected [151]. The loss of HIV replication
in mature DC is a result of a block occurring mainly at the
transcriptional level, which does not affect expression and
localization of NF-B, Sp1, and Sp3 [152].
Microglial cells
In microglial cells, the target for productive infection in the
brain, most of the transcription factors that govern LTR-driven
transcription have the ability to directly or indirectly interact
with the LTR core region. It is interesting that this region is not
bound to any nucleosome within the chromatin and thus, may
freely interact with cellular transcription factors. Sp1 proteins
play an essential stimulating function, as they are able to
anchor to the promoter various cellular transcription factors
(C/EBP/NF–IL-6, CREB/ATF, COUP-TF) by direct or indirect
associations. This unique characteristic leads to HIV-1 strain-
independent transcriptional activation. However, as in other
cell types, the low level of transcription is enhanced upon
stimulation by nuclear relocation of NF-B. Indeed, cultured
human embryonic microglial cells internalize HIV-1 but are
not permissive to viral replication. HIV replication is only
induced when cell cultures are stimulated for 14 days by a
combination of cytokines including IFN-, IL-1, and TNF-,
confirming that activation of the NF-B pathway and cell
maturation facilitate HIV-1 replication [153]. Similarly, adult
cultured microglial cells require the presence of a feeder layer
of glial cells to promote viral replication [154].
In resting T cells within the lymphoid compartments, in the
DC network, and in microglial cells of the CNS, HIV can adopt
a state of proviral latency. Even when viral replication remains
undetectable for a long period of time, virus production can be
restored from a small proportion of cells. Total virus clearance
would require eradication of HIV-1 present within cells that
serve as a latent viral reservoir. This reservoir is constituted by
cells where the preintegration complex resides in a state of
preintegration latency, as well as of cells in which the provirus
is integrated in the host genome. Postintegration latency con-
tributes greatly to the chronicity of the infection and to the
now-established fact that optimal HAART cannot eradicate
HIV (for review, see refs. [155–157]). Some of the proposed
mechanisms for postintegration latency are the lack of activa-
tion-dependent host-cellular factors in resting cells [158, 159],
an insufficient level of Tat or Tat-associated factors [160, 161],
the chromatin structure at the site of the provirus integration
[162], and inefficient export of RNAs for structural proteins
[163]. Thus, targeting latency represents a new challenge to
viral eradication and requires a basic understanding of the
mechanisms underlying proviral expression.
VARIABILITY OF THE LTR AND REGULATION
OF HIV-1 GENE EXPRESSION
Most HIV-1 isolates identified in the pandemic belong to a
group designated M for major. The additional O and N groups
are restricted to patients of Africa [164]. The M-group viruses
have diversified during their world-wide spread to 10 distinct
subtypes or clades, termed A–J, with formation of recombi-
nants and even intergroup recombinant subtypes with mosaic
genomes [165]. The prevalence of the HIV-1 subtypes is
directly related to their geographical area of isolation. The B
subtype predominates in North of Europe and America, and
subtype E predominates in Asia [166]. Some subtypes of
HIV-1, such as C, E, and A, appear to be transmitted more
efficiently than the B clade. Variations in the nucleotide se-
quence of the LTR isolated from different HIV-1 M subtypes
and strains have been reported [13, 167–170]. This LTR
variability may have resulted from adaptation to specific cel-
lular backgrounds to optimize HIV-1 gene transcription. Most
of these LTR mutations occur in consensus-binding sequences
for cellular or viral transcription factors. It is interesting that
despite mutations and alterations of LTR-binding sites (Fig.
2), all these variant LTRs are able to mediate HIV-1 gene
transcription in specific host cell types, which highlights the
great flexibility and adaptability of the cellular transcriptional
machinery.
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Variability of TAR
TAR-independent Tat transactivation has been described in
the presence of intact, proximal LTR elements, suggesting that
Tat alternative interactions with cellular factors may provide
ways to restore efficient transcription [171, 172]. Recent ob-
servations describe how the TAR region of a Tat–TAR binding-
deficient HIV-1 virus can mutate to generate variant isolates
with a functional Tat-binding site [173]. Thus, TAR structure
changes may provide routes for maintaining active viral repli-
cation. HIV-E, described as an HIV-1 strain emerging from
persistently infected HeLa–CD4 cells, replicates better in fi-
broblasts and epithelial cells with respect to the parental T
cell-derived HIV. The cellular adaptation of this variant results
in a TAR duplication and a mutation in the Sp1 II-binding site
[174].
Variability of the core region
Mutations of the Sp1 sites of the LTR abolish Tat transactiva-
tion. In microglial cells, in the absence of Sp1 sites, Tat
restores its activity by recruiting the nuclear receptor COUP-
TF, which substitutes for the Sp1 protein [115]. Thus, adapta-
tive interactions of Tat with cellular transcription factors pro-
vide a solution to overcome specific LTR mutations or a spe-
cific cellular context.
The Y2 strain is a natural variant that harbors a mutation in
the Sp1 III-binding site. This mutation has been observed in a
long-term, nonprogressor, HIV-positive individual [175] and in
a rapid progressor [176]. The Y2 variant replicates poorly in T
cells but replicates well in monocytes, which suggests an
adaptation of Y2 to monocytes by specific compensations for
the loss of Sp1 binding [14].
A cohort of six blood recipients infected from a single
HIV-positive and nonprogressive donor remains free of HIV-
1-related disease with stable and normal CD4 lymphocyte
counts 10–14 years after infection. Survival of these patients is
directly linked to mutations in the U3 region of the LTR or in
the Nef gene [177]. Analysis of LTR sequences of 184 clones
isolated from nonprogressive patients before and after infection
shows that during the nonprogressive phase, the predominant
sequences have a large deletion in a Sp1-binding site and
adjacent promoter site in the U3 part of the LTR. The transition
of a nonprogressive phase to a rapid, progressive infection is
impacted by reorganization of the LTR. When the infection
became progressive, all viruses had intact Sp1 and promoter
sequences and were derived from a minor species present
earlier [178]. These studies suggest that during the nonpro-
gressive phase, the Sp1 enhancer-promoter deletion likely
played a role in attenuating HIV-1 replication.
Variability of the NF-B enhancer region
Analysis of the distinct LTR sequences indicates that each
subtype A–G harbors particular DNA-binding motifs. The LTR
of subtype C harbors three NF-B motifs instead of the two
motifs present in the LTR of other subtypes. Differential reg-
ulation of clade-specific B, C, and E LTRs by NF-B has
revealed that the NF-B sites of subtypes B and E bind
NF-B-related complexes. However, the duplicated B sites of
the C subtype do not compete for NF-B binding [179].
Recently, a variant of a poorly replicative virus has been
described in SupT1 cells [169]. The variant LTR sequence
presents a severe loss of NF-B binding directly linked to an
adaptative point mutation in the second NF-B-binding se-
quence. The new nucleotide sequence binds GABP, a member
of the Ets family. This conversion of NF-B into a GABP site
restores a Tat-responsive activity. This virus adaptation ap-
pears so efficient that the GABP variant overgrows the wild-
type LAI strain in a mixed infection in SupT1 cells. It is
interesting that all 18 subtype E isolates also harbor this
GABP-binding site [169, 180].
Variability of the LTR modulatory region
The USF-binding site is present only in the HIV-1 subtype B,
and the AP-1-binding sites vary from zero to two in different
subtypes [180] and in different virus strains from the same
subtype [74]. A representative subtype D virus circulating in
Uganda harbors a duplication of the LEF-1/TCF-1-binding
sequence, which results in high infectivity [181]. This LEF-1-
binding site duplication also occurs in 38% of HIV-infected
patients within the Vancouver Lymphadenopathy-AIDS Study
[182]. Sequence variations in the ATF/CREB-binding site also
impact transcription factor recruitment and result in more
active isolates [183]. Mutations in the NRRE, which result in
the loss of COUP-TF binding in the brain-derived JR-FL strain
of the subtype B, do not significantly alter transcription [11].
CNS-derived JR-FL and CSF strains also harbor a CNS-spe-
cific TRE sequence [74]. Moreover, phylogenetic analysis of
nervous tissue-derived HIV LTRs are genetically distinct from
that present in other organs such as lung or spleen, indicating
that HIV LTR evolution can occur in a compartmentalized
manner [184].
Fig. 2. Schematic representation of the LTR from different
natural variant HIV-1 strains. Wild-type LTR-binding se-
quences present in the LAI strain are represented by gray
rectangles. Mutated sequences corresponding to new binding
sites are indicated in black. GABP, GA-binding protein.
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Taken together, the HIV-1 LTR variability indicates an
impressive adaptation capacity to the cellular context, which
contributes to HIV-1 infectivity.
HIV-1 GENE TRANSCRIPTION AS A PUTATIVE
TARGET FOR ANTI-HIV STRATEGY
The antiviral molecules currently used for the treatment of HIV
infection belong to two classes: reverse transcriptase and pro-
tease inhibitors. Various other steps of the HIV-1 cell cycle,
including transcription, are potential targets for therapeutic
intervention (for review, see refs. [185, 186]). Increasing stud-
ies describe the possibility of repressing LTR-driven transcrip-
tion by inhibitors of cellular LTR-binding factors such as
NF-B and Sp1 (for review, see ref. [187]).
The major tea catechin epigallocatechin gallate (EGCg)
strongly inhibits HIV-1 gene transcription in LPS-activated
monocytoid THP1 cells. EGCg also impacts other steps of the
HIV-1 replication cycle such as postabsorption entry, viral
particle stability, and reverse transcription [188]. The bistria-
zoloacridone temacrazine inhibits HIV-1 gene transcription
with a high selectivity regarding any other cellular genes.
Temacrazine may impact the binding of factors to positions –1,
–2, and 111 of the LTR, as resistance to this compound was
generated via mutations at these sites [189].
Recent studies demonstrate that engineered zinc-finger tran-
scription factors can inhibit HIV replication in Jurkat T cells.
Zinc-finger proteins designed to bind to the –69/–51 Sp1
region of the LTR and fused to the Kru¨ppel-associated box
repression domain are efficient inhibitors of LTR-driven tran-
scription [190].
Greater specificity might be expected with strategies using
compounds designed to inhibit Tat. As Sp1 and NF-B impact
the expression of a number of cellular genes, Tat represents an
ideal target for inhibiting HIV gene expression. Thus, the
precise understanding of Tat-mediated transcriptional stimu-
latory events is crucial for the development of efficient and
specific anti-HIV strategies. Flavopiridol, an inhibitor of cdk
and P-TEFb, blocks Tat transactivation and HIV replication
[191]. Fluoroquinoline derivatives that selectively inhibit
RNA-binding transactivators are able to repress LTR-driven
transcription and replication by targeting Tat [192, 193]. More
recently, the dominant-negative kinase-inactive mutant cdk9/
hCycT1 chimera was found to inhibit Tat activity and thus,
HIV replication in human cells [194]. Another recent study
demonstrates that a chimeric, small nucleolar RNA–TAR de-
coy, which affects the nucleolar trafficking of Tat, potently
inhibits HIV-1 replication in lymphoblastoid CEM cells [195].
We have recently demonstrated that in microglial cells, over-
expression of the nuclear cofactor CTIP2 inhibits HIV-1 gene
transcription and replication by relocating Tat to transcription-
ally inactive regions of the chromatin via HP1. Active, in-
hibitory CTIP2-derived peptides could be further tested in an
antiviral strategy [132]. Finally, inhibitors that block the in-
duction pathways of the Tat cofactors cdk9 and CycT1, known
to be regulated by extracellular stimuli [196], could also ulti-
mately interfere with Tat function and affect HIV transcription.
Identification of additional molecules that selectively target the
Tat transactivation process remains a line of investigation that
provides an interesting opportunity to block HIV-1 expression.
The last decade of research on the mechanisms governing
gene transcription has highlighted the importance of chromatin
structure and remodeling. Multiprotein complexes help acti-
vate gene expression by altering chromatin to promote a better
access of sequence-specific proteins and of the general tran-
scription machinery to DNA regulatory sequences [197]. Acet-
ylation/deacetylation events are implicated in chromatin re-
modeling of the HIV-1 promoter region, as well as in modu-
lating the activity of cellular or viral transcription factors
implicated in LTR-driven regulation. LTR-binding transcrip-
tion factors represent good candidates for the specific targeting
of acetyltransferases and deacetylases to the HIV-1 promoter,
thereby regulating the acetylation level of histones near the
LTR (for review, see refs. [198, 199]). In the case of HIV-1,
acetylation could also modulate the activity of some compo-
nents of the basal transcription machinery as well as LTR-
binding transcription factors such as Sp1, p53, p65, and p50
subunits of NF-B (for review, see ref. [200]). It is interesting
that Tat itself is subjected to acetylation events (for review, see
ref. [199]). This presently active area of research will help shed
new light on the mechanisms of active transcription and
postintegration latency of the HIV provirus. As these regula-
tory mechanisms become better understood, it is likely that
new therapeutic targets will become available.
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